Which GLP-1 is Best for Me? Biomarkers & Genetics Guide

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The right GLP-1 medication for you depends on your metabolic goals, clinical profile, and how your body's appetite-regulation pathways may respond to different compounds. Research shows semaglutide and tirzepatide have distinct efficacy profiles, with tirzepatide demonstrating greater average weight loss in head-to-head trials, but individual response varies significantly.

Beyond efficacy data, understanding your genetic predispositions in GLP-1 receptor and metabolic pathways can support a more personalized treatment discussion with your provider. This guide integrates clinical evidence, biomarker context, and actionable steps to help you evaluate GLP-1 options with confidence.

GLP-1 vs. GLP-1/GIP Agonists: Mechanism and Clinical Outcomes

GLP-1 receptor agonists (semaglutide) activate the GLP-1 receptor, which regulates appetite, glucose control, and gastric emptying. GLP-1/GIP dual agonists (tirzepatide) activate both GLP-1 and GIP receptors, potentially engaging additional metabolic pathways and delivering greater weight loss in clinical trials.

A 2023 NEJM trial showed tirzepatide achieved up to 22% body weight loss versus 16% for semaglutide at comparable doses over 68 weeks. However, both classes carry similar side effect profiles. Your clinical goals, gastrointestinal tolerance, and underlying metabolic markers should guide the choice between single and dual agonists.

Key Clinical Markers That May Influence Your GLP-1 Choice

Beyond medication class, several biomarkers and clinical features may provide context for your provider's recommendation. Fasting glucose, insulin resistance (HOMA-IR), HbA1c, lipid panel, and body composition all inform whether semaglutide or tirzepatide may align with your metabolic profile.

Clinical Marker	Why It Matters for GLP-1 Selection
Fasting Glucose & HbA1c	Higher baseline glucose may respond more robustly to GLP-1/GIP dual agonists; both classes improve glycemic control.
Insulin Resistance (HOMA-IR)	Elevated HOMA-IR suggests metabolic dysfunction; tirzepatide's dual pathway engagement may provide additional benefit.
Triglycerides & LDL	GLP-1 agonists improve lipid profiles; tirzepatide shows larger reductions in some trials, supporting cardiovascular metabolic goals.
Baseline BMI & Weight Loss History	Higher BMI and prior weight loss resistance may benefit from tirzepatide's greater average weight loss efficacy.

Genetic Predispositions in GLP-1 and Metabolic Pathways

Variants in the GLP1R gene (rs6923761) and GIPR gene (rs1800437) influence how your appetite-regulation receptors function at baseline. Specific genotypes may predispose you to stronger or more modest responses to GLP-1 or GLP-1/GIP signaling, informing treatment expectations.

FTO and MC4R variants relate to baseline appetite control and energy expenditure. Understanding your genetic predispositions can contextualize why one GLP-1 option might align better with your metabolic phenotype. These insights should always be interpreted with your healthcare provider—genetics reveal predispositions, not certainties.

Safety Considerations and Who Should Start GLP-1 Therapy

GLP-1 agonists are contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pregnancy, severe renal impairment, and active pancreatitis require medical evaluation. Common side effects—nausea, vomiting, constipation—are dose-dependent and often transient.

Your provider will assess thyroid history, gastrointestinal tolerance, cardiovascular status, and kidney function before recommending semaglutide or tirzepatide. Compounded formulations from licensed 503A pharmacies offer flexible dosing and cost accessibility, but medical supervision remains essential throughout treatment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals your genetic predispositions in GLP1R, GIPR, FTO, and MC4R pathways. This context may help support a more informed conversation with your provider about whether semaglutide, tirzepatide, or a dual-agonist protocol aligns with your metabolic biology.

The genetic test identifies variants that influence appetite regulation and receptor sensitivity—not exact medication response. When combined with your clinical biomarkers (glucose, insulin resistance, lipids) and treatment goals, this genetic predisposition data can inform personalized dosing and compound selection strategies.

By understanding your genetic predispositions alongside your current metabolic status, you and your provider can make a more evidence-informed decision about which GLP-1 option to begin with, expected timelines for dose optimization, and whether compounded semaglutide, tirzepatide, or dual-agonist protocols may best support your health goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.